RxDoctor Payments Data

Richard Podolin, MD

Cardiovascular Disease · San Francisco, CANPI 1295876860

Payments from drug & device makers

$19,585in general payments, 2019–2025

Across 846 payments — averaging $23.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$2K
  • Amgen$2K
  • Abbott$1K
  • AstraZeneca$1K
  • Boehringer Ingelheim$1K
  • E.r. Squibb & Sons, L.L.C.$1K
  • plus $11K from 45 others

What the payments were for

  • Travel & lodging$1,0065%
  • Food & beverage$18,55495%
  • Education$240%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$19,585 in reported general payments places this provider in the 80th percentile of 2,184 cardiovascular disease providers in California.

See all cardiovascular disease providers in California

Medicare billing

Part B allowed, 2024
$220,682
Medicare patients
371
Services billed
1,962

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VyndamaxTafamidis50$1,525,734
EliquisApixaban320$425,885
XareltoRivaroxaban72$103,191
EntrestoSacubitril/Valsartan53$88,890
MultaqDronedarone Hcl20$39,183
Repatha SureclickEvolocumab38$38,231
JardianceEmpagliflozin23$37,249
Praluent PenAlirocumab11$9,010
Dofetilide31$7,599
LivaloPitavastatin Calcium11$7,270
EdarbyclorAzilsartan Med/Chlorthalidone17$6,902
Valsartan175$5,431
Atorvastatin Calcium479$4,954
Metoprolol Succinate277$4,901
Ezetimibe159$4,502

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerVyndamax, Eliquis$776$1,951,619370 claims
Johnson & JohnsonXarelto$880$103,19172 claims
NovartisEntresto$1,655$88,89053 claims
Sanofi-aventis U.S. LLCMultaq$633$39,18320 claims
Boehringer IngelheimJardiance$1,331$37,24923 claims
Kowa Pharmaceuticals America, Inc.Livalo$169$7,27011 claims
Arbor Pharmaceuticals, Inc.Edarbyclor$23$6,90217 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,184 cardiovascular disease providers in California.

Other cardiovascular disease in San Francisco

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →